| NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16110-833-10 | 16110-833 | HUMAN PRESCRIPTION DRUG | Tazorac | tazarotene | GEL | CUTANEOUS | 20200221 | N/A | NDA | NDA020600 | Almirall, LLC | TAZAROTENE | .5 mg/g | 1 TUBE in 1 CARTON (16110-833-10) / 100 g in 1 TUBE |
| 16110-833-30 | 16110-833 | HUMAN PRESCRIPTION DRUG | Tazorac | tazarotene | GEL | CUTANEOUS | 20200221 | N/A | NDA | NDA020600 | Almirall, LLC | TAZAROTENE | .5 mg/g | 1 TUBE in 1 CARTON (16110-833-30) / 30 g in 1 TUBE |
| 16110-042-10 | 16110-042 | HUMAN PRESCRIPTION DRUG | Tazorac | tazarotene | GEL | CUTANEOUS | 20200221 | N/A | NDA | NDA020600 | Almirall, LLC | TAZAROTENE | 1 mg/g | 1 TUBE in 1 CARTON (16110-042-10) / 100 g in 1 TUBE |
| 16110-042-30 | 16110-042 | HUMAN PRESCRIPTION DRUG | Tazorac | tazarotene | GEL | CUTANEOUS | 20200221 | N/A | NDA | NDA020600 | Almirall, LLC | TAZAROTENE | 1 mg/g | 1 TUBE in 1 CARTON (16110-042-30) / 30 g in 1 TUBE |